Wnt pathway in osteosarcoma, from oncogenic to therapeutic.
about
Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted TherapiesGermline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.Wnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma.Sox9 regulates hyperexpression of Wnt1 and Fzd1 in human osteosarcoma tissues and cells.Down regulation of Wnt signaling mitigates hypoxia-induced chemoresistance in human osteosarcoma cells.Wnt/β-catenin pathway in bone cancers.Investigation of osteosarcoma genomics and its impact on targeted therapy: an international collaboration to conquer human osteosarcoma.Whole exome sequencing of a single osteosarcoma case--integrative analysis with whole transcriptome RNA-seq data.Genomic instability of osteosarcoma cell lines in culture: impact on the prediction of metastasis relevant genes.Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma.Inhibition of oleandrin on the proliferation show and invasion of osteosarcoma cells in vitro by suppressing Wnt/β-catenin signaling pathway.Molecular profiling of childhood cancer: Biomarkers and novel therapiesThe molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study.Deciphering signaling networks in osteosarcoma pathobiology.Mesenchymal Tumors Can Derive from Ng2/Cspg4-Expressing Pericytes with β-Catenin Modulating the Neoplastic Phenotype.A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model.Significance of MTA1 in the molecular characterization of osteosarcoma.Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies.Involvement of c-Fos in cell proliferation, migration, and invasion in osteosarcoma cells accompanied by altered expression of Wnt2 and Fzd9.LDOC1 regulates Wnt5a expression and osteosarcoma cell metastasis and is correlated with the survival of osteosarcoma patients.Genetic factors conferring metastasis in osteosarcoma.S-Adenosylmethionine Affects ERK1/2 and Stat3 Pathways and Induces Apotosis in Osteosarcoma Cells.Molecular genetics of osteosarcoma.The Overexpression of CARM1 Promotes Human Osteosarcoma Cell Proliferation through the pGSK3β/β-Catenin/cyclinD1 Signaling Pathway.High Expression of XRCC6 Promotes Human Osteosarcoma Cell Proliferation through the β-Catenin/Wnt Signaling Pathway and Is Associated with Poor Prognosis.TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma.Gene expression profile comparison between colorectal cancer and adjacent normal tissues.Baicalein inhibits progression of osteosarcoma cells through inactivation of the Wnt/β-catenin signaling pathway.Antitumor activity of resveratrol against human osteosarcoma cells: a key role of Cx43 and Wnt/β-catenin signaling pathway.Logistic regression analysis for the identification of the metastasis-associated signaling pathways of osteosarcoma.The tumor suppressive role of RASSF1A in osteosarcoma through the Wnt signaling pathway.Biglycan Regulates MG63 Osteosarcoma Cell Growth Through a LPR6/β-Catenin/IGFR-IR Signaling Axis
P2860
Q26745742-4EDF9094-C512-45DF-ACB5-7E52BB3A479DQ30235105-FEE69C35-9278-4456-9EAC-6286F5997DE6Q33685717-6E524A00-E625-4E8B-9C2A-A3258A7B15C9Q34121370-4E568AE3-056F-4D0A-A92A-ED798501D794Q34408337-23ED811A-09A4-47E7-90AD-06EA8E14816AQ34663910-FFEB555C-9E58-45BE-B222-E63616060FB9Q35020434-400D3ADF-6B74-4C07-81DD-0E6F1E27B7A4Q35511058-E44FDE2D-4DD6-409D-98D5-19E582D3F087Q35625523-FE5AEB89-8C79-43D6-8316-E75AB4F50996Q35928872-642457BC-70E5-4A56-B7C6-570FD5E4AAECQ36131540-0CF060E8-B17C-4D8D-B17F-7B566A2AA8BDQ36250783-F8C72CF5-2143-491F-A2EF-BCF6B5757D4EQ36873828-0574CA8C-6440-41E6-B6AC-770E2AAA9DA8Q37106930-DAFFF7B5-FB7C-4983-825E-4EAE83979970Q37131523-6825A379-9090-423D-A7C3-9B1B3413369BQ37225229-A522BABC-8DA5-4A07-8F77-3C4CAE877042Q38260257-43A0116A-A9D3-4894-90ED-26F1DF0B8775Q38379348-F9E3E369-562D-4484-89A9-EC048B9D9365Q38698563-1FB4C830-8273-4F49-8F70-5F26E532C055Q38714711-4BC315D9-FFB4-4962-9C33-8F21F2F5FF1AQ38806986-74ECB2B1-AE24-4516-ADCC-C0355C0FC43DQ38853093-072FA752-BDB6-4500-A8F4-041AB174E305Q38985480-E955F304-2ED1-4519-A23E-87BE9EB3886FQ41036174-EF4BA05B-4DC7-44CC-B305-0AEFF6682740Q42397166-AA3DF765-43E1-4EA6-B071-C6BF6FEE716BQ45894158-6FDA5F13-5737-45BD-B509-EF6B1951D9BAQ47099108-E9759EC9-FD81-42D4-A44D-AF80CD1425CFQ47115188-D80A5E2F-F0CC-44F1-8780-ED7C5B707405Q49399012-A9784FDA-11ED-4726-9E4D-4C0A5CA89744Q50068247-40932E17-6BDC-457B-88BC-47BC08271559Q52889828-FEB775C0-D8EF-43CD-BEC4-CD0B8119F75FQ58573362-2F3FB598-A342-4251-8556-D9A00E14D158
P2860
Wnt pathway in osteosarcoma, from oncogenic to therapeutic.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Wnt pathway in osteosarcoma, from oncogenic to therapeutic.
@en
type
label
Wnt pathway in osteosarcoma, from oncogenic to therapeutic.
@en
prefLabel
Wnt pathway in osteosarcoma, from oncogenic to therapeutic.
@en
P2093
P2860
P356
P1476
Wnt pathway in osteosarcoma, from oncogenic to therapeutic.
@en
P2093
P2860
P304
P356
10.1002/JCB.24708
P577
2014-04-01T00:00:00Z